{"slug":"ipamorelin","title":"ipamorelin","body":"## Overview\nEvidence is being populated by Grok web search.","register":"standard","tags":[],"style":{},"claims":[{"id":"c1","text":"2024 animal study showing ipamorelin (and anamorelin) reduces cisplatin-induced weight loss in ferrets during delayed phase when given intraperitoneally, with no effect on emesis itself.","section":"mechanism","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair"},{"id":"c2","text":"2026 narrative review discussing ipamorelin among unapproved peptides, noting animal model benefits but scarce human safety data and regulatory concerns for sports medicine use.","section":"what_is_known","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair"}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39043357/","title":"The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism","quote":"This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. ... Neither of compounds administered i.p. had any effect on cisplatin-induced acute or delayed emesis, but both inhibited associated cisplatin-induced weight loss on the last day of delayed phase (48-72 h) by approximately 24 %.","summary":"2024 animal study showing ipamorelin (and anamorelin) reduces cisplatin-induced weight loss in ferrets during delayed phase when given intraperitoneally, with no effect on emesis itself.","author":"","publisher":"","date":"","claim_ids":["c1"]},{"id":"s2","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41966639/","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","quote":"Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 ... ipamorelin, MOTS-C ... Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients.","summary":"2026 narrative review discussing ipamorelin among unapproved peptides, noting animal model benefits but scarce human safety data and regulatory concerns for sports medicine use.","author":"","publisher":"","date":"","claim_ids":["c2"]}],"prov":{"model":"grok/grok-4.3","action":"write"}}